Holen Sie sich die Stockscreener-App
7.36
1.94%
0.14
Schlusskurs vom Vortag:
$7.22
Offen:
$7.32
24-Stunden-Volumen:
200.38K
Relative Volume:
1.46
Marktkapitalisierung:
$222.68M
Einnahmen:
$1.78M
Nettoeinkommen (Verlust:
$-151.77M
KGV:
-1.2694
EPS:
-5.7981
Netto-Cashflow:
$-77.37M
1W Leistung:
-0.67%
1M Leistung:
-18.94%
6M Leistung:
+17.57%
1J Leistung:
-28.82%
1-Tages-Spanne:
$7.29
$8.05
1-Wochen-Bereich:
$7.01
$8.05
52-Wochen-Spanne:
$5.60
$11.00
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
Firmenname
Cartesian Therapeutics Inc
Sektor
Branche
Telefon
301-348-8698
Adresse
7495 NEW HORIZON WAY, FREDERICK
Compare RNAC vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
7.36 | 224.19M | 1.78M | -151.77M | -77.37M | -5.7981 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-09 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-09 | Eingeleitet | Wedbush | Outperform |
| 2024-12-19 | Eingeleitet | BTIG Research | Buy |
| 2024-08-06 | Eingeleitet | TD Cowen | Buy |
| 2024-07-02 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-06-04 | Eingeleitet | Oppenheimer | Outperform |
| 2024-05-24 | Eingeleitet | Mizuho | Buy |
| 2024-04-23 | Bestätigt | H.C. Wainwright | Buy |
| 2024-04-23 | Eingeleitet | Leerink Partners | Outperform |
| 2023-08-18 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2022-06-14 | Bestätigt | Needham | Buy |
| 2022-06-06 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-01-26 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-10-01 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-10-01 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-06-12 | Herabstufung | Stifel | Buy → Hold |
| 2020-04-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-01-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-01-21 | Eingeleitet | William Blair | Outperform |
| 2018-06-27 | Eingeleitet | Janney | Buy |
| 2017-03-30 | Bestätigt | UBS | Buy |
Alle ansehen
Cartesian Therapeutics Inc Aktie (RNAC) Neueste Nachrichten
RNAC Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
H.C. Wainwright reiterates Cartesian Therapeutics stock rating at buy By Investing.com - Investing.com Canada
RNAC Reiterated by Needham -- Price Target Maintained at $40 - GuruFocus
Needham reiterates Buy rating on Cartesian Therapeutics, $40 price target - TradingView
Cartesian Therapeutics Reports Encouraging Descartes-08 Retreatment Data - TipRanks
Cartesian Therapeutics Unveils Phase 2 Descartes-08 Retreatment Results in Myasthenia Gravis Patients - kalkinemedia.com
Cartesian Therapeutics presents Descartes-08 retreatment data at AANEM for ongoing Phase 3 MG trial - Traders Union
Cartesian Therapeutics Announces Additional Retreatment Data For Descartes-08 Highlighting Deep And Durable Responses In Patients With Myasthenia Gravis - TradingView
Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis - GlobeNewswire
Cartesian Therapeutics Inc. (NASDAQ: RNAC) Share Price, RNAC Stock News, RNAC Share Price & Updates - Kalkine
RNAC Q2 2026 Earnings: Cartesian Therapeutics Reports Surprise Positive EPS of $0.61, Beating Estimates by 168.86%Profit Margin Analysis - dars.gov.et
Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewswire
Cartesian Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Three investor events are expected in September. Two talks may stream online. - Stock Titan
Insiders Who Sold Cartesian Therapeutics Made The Right Call As Market Cap Slides By US$33m - simplywall.st
Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock? - qz.com
Cartesian (RNAC) Price: Retreats 1.86% to $10.04 at the Close; Technical View: Traders Can Monitor the $9.54-$10.54 Range in the Latest ReadingPrice Target - vinanet.vn
Cartesian (RNAC) Earnings Report: EPS Comes in Above Forecast in the Latest Reading; Market Reaction: The Stock Ends Up 14.02% in the Latest SessionEarnings Quality Score - vinanet.vn
Cartesian (RNAC) Results at a Glance: EPS Prints Above Forecast in the Current Update; Latest Reaction: The Stock Gains 9.78% in the Latest ReadingCore Business Growth - vinanet.vn
Cartesian (RNAC) Q2 2026 Earnings: The Bottom-Line Figure Beats Its Comparison in the Latest Session; Closing Reaction: The Stock Gains 0.22% at the CloseMid-Term Outlook - vinanet.vn
RNAC Reiterated by Wedbush -- Rating Maintained at Outperform - GuruFocus
Wedbush Reiterates Outperform Rating for Cartesian Therapeutics (NASDAQ:RNAC) - MarketBeat
Cartesian Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | RNAC | US8162123025 - marketscreener.com
Barclays PLC (RNAC) discloses 1.76M-share, 5.99% holding in Cartesian Therapeutics - Stock Titan
Mizuho Securities Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Maintains Target Price $40 - Moomoo
HC Wainwright Analysts Lower Earnings Estimates for RNAC - MarketBeat
Cartesian Therapeutics (RNAC) Slips 2.85% as Shares Test Key Support at $8.08Weekly Profile - dars.gov.et
Cartesian Therapeutics Advances RNA Cell Therapy Pipeline; Wedbush Sets $38 Price Target - RTTNews
RNAC Q2 2026 Earnings: Positive EPS Surprise Masks Pre-Revenue Biotech ChallengesProfit Cycle Analysis - dars.gov.et
Cartesian Therapeutics (NASDAQ:RNAC) Announces Quarterly Earnings Results - MarketBeat
Cartesian Therapeutics (NASDAQ:RNAC) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
A Quick Look at Today's Ratings for Cartesian Therapeutics(RNAC.US), With a Forecast Between $25 to $44 - Moomoo
Cartesian Therapeutics Inc (RNAC) Stock News Today - TradingKey
Cartesian Therapeutics earnings beat by $1.34, revenue fell short of estimates - Investing.com Canada
Cartesian Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Cartesian Therapeutics Q2 2026 earnings: R&D spending rises as Phase 3 advances - TradingKey
Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Cartesian Therapeutics Reports Q2 2026 Results, Advances Descartes-08 Clinical Trials and WestGene In Vivo Partnership - Quiver Quantitative
Cartesian Therapeutics reports Q2 2026: $149.3M cash; net income $15.8M; Phase 3 MG data expected 1Q27 - TradingView
Cartesian Therapeutics (Nasdaq: RNAC) Q2 earnings boosted by CVR revaluation - Stock Titan
Cartesian Therapeutics 2Q Research and Development Expenses $20.4M >RNAC - Moomoo
Cartesian Therapeutics Q2 Net Income Reaches $15.8 Million As Pipeline Advances - Quiver Quantitative
RNAC Q2'26 Earnings: EPS estimate is (0.88) USD - TradingView
Cartesian Therapeutics Inc expected to post a loss of 87 cents a shareEarnings Preview - TradingView
Price to sales forward of Cartesian Therapeutics, Inc. – NASDAQ:RNAC - TradingView
Cartesian Therapeutics (NASDAQ:RNAC) Raised to Hold at Zacks Research - MarketBeat
RNAC Q2'26 Earnings: revenue estimate is 179.67K USD - TradingView
Cartesian Therapeutics, Inc. Revenue Breakdown – NASDAQ:RNAC - TradingView
Cartesian Therapeutics (NASDAQ:RNAC) Shares Down 1.1%Here's What Happened - MarketBeat
Cartesian Therapeutics Inc (RNAC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cartesian Therapeutics Inc (RNAC) Cash Flow - TradingKey
Finanzdaten der Cartesian Therapeutics Inc-Aktie (RNAC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):